BR0213738A - proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma - Google Patents
proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucomaInfo
- Publication number
- BR0213738A BR0213738A BRPI0213738-0A BR0213738A BR0213738A BR 0213738 A BR0213738 A BR 0213738A BR 0213738 A BR0213738 A BR 0213738A BR 0213738 A BR0213738 A BR 0213738A
- Authority
- BR
- Brazil
- Prior art keywords
- bmp
- glaucoma
- treatment
- antagonist
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
Abstract
"PROTEìNAS MORFOGêNICAS óSSEAS (BMP), RECEPTORES DE BMP E PROTEìNAS DE LIGAçãO DE BMP E SEU USO NO DIAGNóSTICO E NO TRATAMENTO DE GLAUCOMA". A presente invenção fornece processos e kits para o diagnóstico e para o tratamento do glaucoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33485201P | 2001-10-31 | 2001-10-31 | |
PCT/US2002/035251 WO2003055443A2 (en) | 2001-10-31 | 2002-10-31 | Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213738A true BR0213738A (pt) | 2006-11-21 |
Family
ID=23309139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0213738-0A BR0213738A (pt) | 2001-10-31 | 2002-10-31 | proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma |
Country Status (16)
Country | Link |
---|---|
US (5) | US20050118585A1 (pt) |
EP (2) | EP1440159B1 (pt) |
JP (2) | JP4255382B2 (pt) |
KR (4) | KR100996226B1 (pt) |
CN (2) | CN1685055A (pt) |
AT (1) | ATE349554T1 (pt) |
BR (1) | BR0213738A (pt) |
CA (1) | CA2463143A1 (pt) |
DE (1) | DE60217152T2 (pt) |
ES (1) | ES2278079T3 (pt) |
HK (1) | HK1069851A1 (pt) |
MX (1) | MXPA04003697A (pt) |
PL (2) | PL373863A1 (pt) |
RU (3) | RU2336902C2 (pt) |
WO (1) | WO2003055443A2 (pt) |
ZA (1) | ZA200402662B (pt) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2278079T3 (es) * | 2001-10-31 | 2007-08-01 | Alcon, Inc. | Proteinas morfogenicas oseas (bmp), receptores de bmp y proteinas de union a bmp y su utilizacion en el diagnostico y en el tratamiento del glaucoma. |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
DE602004024300D1 (de) | 2003-05-28 | 2010-01-07 | Takeda Pharmaceutical | Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs |
CA2475769C (en) * | 2003-08-28 | 2018-12-11 | Veridex, Llc | Colorectal cancer prognostics |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
CA2567810A1 (en) | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
WO2006060533A2 (en) | 2004-12-01 | 2006-06-08 | Genentech, Inc. | Conjugates of 1, 8-bis-naphthalimides with an antibody |
WO2007028212A1 (en) * | 2005-09-08 | 2007-03-15 | Apollo Life Sciences Limited | Noggin and chimeric molecules thereof |
US20080051361A1 (en) * | 2006-08-24 | 2008-02-28 | Alcon Manufacturing, Ltd. | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions |
CN101652387A (zh) | 2006-11-02 | 2010-02-17 | 阿塞勒隆制药公司 | Alk1受体和配体拮抗剂及其用途 |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
EP2099471A2 (en) | 2006-12-08 | 2009-09-16 | Acceleron Pharma, Inc. | Uses of cerberus, coco and derivatives thereof |
CN102099374B (zh) | 2008-05-02 | 2016-06-08 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
US8900589B2 (en) | 2008-07-15 | 2014-12-02 | Genetech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
IN2012DN03025A (pt) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
JP5808331B2 (ja) | 2009-10-16 | 2015-11-10 | ザ スクリプス リサーチ インスティテュート | 多能性細胞の誘導法 |
WO2011116212A2 (en) * | 2010-03-17 | 2011-09-22 | Oncomed Pharmaceuticals, Inc. | Bone morphogenetic protein receptor binding agents and methods of their use |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
JP5987053B2 (ja) | 2011-05-12 | 2016-09-06 | ジェネンテック, インコーポレイテッド | フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法 |
AU2012322607B2 (en) | 2011-10-14 | 2017-02-16 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
CN104321342B (zh) | 2012-03-15 | 2017-12-22 | 首尔大学校产学协力团 | Gremlin‑1抗体 |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
CA2887899C (en) | 2012-10-12 | 2020-03-31 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
EP2906298B1 (en) | 2012-10-12 | 2018-10-03 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
ME03486B (me) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
LT2906253T (lt) | 2012-10-12 | 2018-10-10 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-psma antikūno konjugatas |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
AR096287A1 (es) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | Pirrolobenzodiacepinas y conjugados |
CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
MX369574B (es) | 2013-03-14 | 2019-11-13 | Regeneron Pharma | Anticuerpos humanos contra grem1. |
US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
MX2016007826A (es) | 2013-12-16 | 2017-03-31 | Genentech Inc | Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco. |
BR112016012410A2 (pt) | 2013-12-16 | 2017-09-26 | Genentech Inc | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica |
WO2016007742A1 (en) * | 2014-07-09 | 2016-01-14 | Riester Scott M | Treating rotator cuff conditions |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
WO2017011762A1 (en) | 2015-07-16 | 2017-01-19 | Mayo Foundation For Medical Education And Research | Treating rotator cuff conditions |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
KR101921784B1 (ko) * | 2015-10-13 | 2018-11-23 | 사회복지법인 삼성생명공익재단 | 그램린-1을 코딩하는 뉴클레오타이드 또는 그램린-1을 유효성분으로 포함하는 안 질환 예방 또는 치료용 약제학적 조성물 |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN105807065B (zh) * | 2016-03-16 | 2018-10-02 | 沈慧勇 | BMP2和Noggin联合使用在制备强直性脊柱炎诊断试剂盒中的应用 |
EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (ja) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート |
CN106086229B (zh) * | 2016-08-26 | 2019-08-16 | 广东省农业科学院动物科学研究所 | 鸡生长性状相关的分子标记及其鉴别方法和应用 |
JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
KR20200032243A (ko) | 2017-02-08 | 2020-03-25 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
CN108531608B (zh) * | 2018-01-24 | 2020-06-30 | 华南农业大学 | Bmp6基因作为黑山羊产羔数性状的分子标记 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
TW202037381A (zh) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | 綴合化學降解誘導劑及使用方法 |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
US20220259558A1 (en) * | 2019-05-15 | 2022-08-18 | Novo Nordisk A/S | Methods for obtaining eye field progenitor cells from human pluripotent stem cells |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
IT1224795B (it) * | 1988-12-01 | 1990-10-24 | Sigma Tau Ind Farmaceuti | Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento |
SK136693A3 (en) * | 1991-06-05 | 1994-10-05 | Procter & Gamble | Therapeutic compositions for osteoinduction |
US5364884A (en) * | 1993-01-21 | 1994-11-15 | Baylor College Of Medicine | Arginine compounds as ocular hypotensive agents |
AU702163B2 (en) * | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
US5606043A (en) * | 1994-11-03 | 1997-02-25 | The Regents Of The University Of California | Methods for the diagnosis of glaucoma |
US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
US6040431A (en) * | 1995-06-07 | 2000-03-21 | Stryker Corporation | Single chain analogs of the TGF-β superfamily (morphons) |
EP0852580B1 (de) * | 1995-08-31 | 2000-10-25 | Lonza Ag | Verfahren zur herstellung von dihydroxypyrimidin-derivaten |
CA2271235A1 (en) * | 1996-11-08 | 1998-05-14 | University Of Iowa Research Foundation | Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses |
WO1998020889A1 (en) * | 1996-11-15 | 1998-05-22 | Creative Biomolecules Inc | Morphogen peptide-induced regeneration of sense perceptory tissues |
EP0943014B1 (en) * | 1996-12-05 | 2007-02-21 | Alcon Manufacturing, Ltd. | Methods for diagnosing glaucoma and discovering anti-glaucoma drugs |
US5989885A (en) * | 1997-01-10 | 1999-11-23 | Myriad Genetics, Inc. | Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer |
WO1998040508A1 (en) * | 1997-03-14 | 1998-09-17 | Selective Genetics, Inc. | Adenoviral vectors with modified tropism |
US6207450B1 (en) * | 1998-04-15 | 2001-03-27 | University Of Iowa Research Foundation | Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
CA2365089A1 (en) * | 1999-02-26 | 2000-08-31 | Hibergen Limited | Identification of genes having a role in the presentation of diabetic nephropathy |
AU4073600A (en) * | 1999-04-09 | 2000-11-14 | Human Genome Sciences, Inc. | Bone morphogenic proteins |
EP1179052A4 (en) * | 1999-05-07 | 2004-12-15 | Human Genome Sciences Inc | SERINE PROTEASES |
CA2387696A1 (en) * | 1999-06-11 | 2000-12-21 | Human Genome Sciences, Inc. | 48 human secreted proteins |
WO2002077006A1 (en) * | 2001-03-23 | 2002-10-03 | Human Genome Sciences, Inc. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
WO2002085909A1 (en) | 2001-04-20 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
ES2278079T3 (es) * | 2001-10-31 | 2007-08-01 | Alcon, Inc. | Proteinas morfogenicas oseas (bmp), receptores de bmp y proteinas de union a bmp y su utilizacion en el diagnostico y en el tratamiento del glaucoma. |
WO2006014411A1 (en) | 2004-07-02 | 2006-02-09 | Strasbaugh | Method and system for processing wafers |
-
2002
- 2002-10-31 ES ES02802562T patent/ES2278079T3/es not_active Expired - Lifetime
- 2002-10-31 KR KR1020047005671A patent/KR100996226B1/ko not_active IP Right Cessation
- 2002-10-31 EP EP02802562A patent/EP1440159B1/en not_active Expired - Lifetime
- 2002-10-31 MX MXPA04003697A patent/MXPA04003697A/es active IP Right Grant
- 2002-10-31 AT AT02802562T patent/ATE349554T1/de not_active IP Right Cessation
- 2002-10-31 KR KR1020107026384A patent/KR101072867B1/ko not_active IP Right Cessation
- 2002-10-31 CN CNA028209176A patent/CN1685055A/zh active Pending
- 2002-10-31 CA CA002463143A patent/CA2463143A1/en not_active Withdrawn
- 2002-10-31 CN CNA2006101467420A patent/CN1966725A/zh active Pending
- 2002-10-31 KR KR1020117005285A patent/KR20110032003A/ko not_active Application Discontinuation
- 2002-10-31 JP JP2003556021A patent/JP4255382B2/ja not_active Expired - Fee Related
- 2002-10-31 RU RU2004116308/15A patent/RU2336902C2/ru not_active IP Right Cessation
- 2002-10-31 PL PL02373863A patent/PL373863A1/xx not_active Application Discontinuation
- 2002-10-31 KR KR1020107001960A patent/KR20100013352A/ko active Application Filing
- 2002-10-31 BR BRPI0213738-0A patent/BR0213738A/pt not_active Application Discontinuation
- 2002-10-31 EP EP08019507A patent/EP2053135A1/en not_active Withdrawn
- 2002-10-31 DE DE60217152T patent/DE60217152T2/de not_active Expired - Lifetime
- 2002-10-31 US US10/492,380 patent/US20050118585A1/en not_active Abandoned
- 2002-10-31 PL PL396553A patent/PL214839B1/pl unknown
- 2002-10-31 US US10/286,152 patent/US7405192B2/en not_active Expired - Fee Related
- 2002-10-31 WO PCT/US2002/035251 patent/WO2003055443A2/en active Application Filing
-
2004
- 2004-04-05 ZA ZA200402662A patent/ZA200402662B/en unknown
- 2004-12-16 HK HK04110026A patent/HK1069851A1/xx not_active IP Right Cessation
-
2008
- 2008-04-21 US US12/106,653 patent/US7744873B2/en not_active Expired - Fee Related
- 2008-06-03 RU RU2008122296/15A patent/RU2008122296A/ru not_active Application Discontinuation
- 2008-09-08 JP JP2008230352A patent/JP2008301834A/ja active Pending
-
2010
- 2010-04-23 US US12/766,056 patent/US8063013B2/en not_active Expired - Fee Related
-
2011
- 2011-10-26 US US13/281,816 patent/US8389496B2/en not_active Expired - Fee Related
-
2012
- 2012-05-16 RU RU2012120343/15A patent/RU2012120343A/ru not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213738A (pt) | proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma | |
BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
MA28010A1 (fr) | Derives de piperazine et leur utilisation comme agents therapeutiques | |
BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
BR0210241A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
ATE202706T1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
ES2172670T3 (es) | Pirrolpirimidinas y procedimientos para su preparacion. | |
FI970489A0 (fi) | Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät doksepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon | |
NO20025450D0 (no) | Ny farmasöytisk sammensetning | |
ATE365550T1 (de) | Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie | |
WO2003047513A3 (en) | Method for treating ocular hypertension | |
MA27305A1 (fr) | Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales | |
DE60219614D1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
ATE487514T1 (de) | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom | |
BR0210238A (pt) | Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma | |
BR9907715A (pt) | Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose | |
BRPI0407693A (pt) | uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos | |
BR0316775A (pt) | Novos análogos de benzopirano e seu uso para o tratamento de glaucoma | |
EA200300448A1 (ru) | Композиции, включающие соединения модафинила | |
DE60120961D1 (de) | Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen | |
SE8901149D0 (sv) | Medel foer inducering respektive foerhindrande av pupillkonstriktion i oegat | |
SE9201425D0 (sv) | Method and means for preventing constriction of the pupil in the eye | |
BR0317445A (pt) | Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12P 19/34 , C12Q 1/68 Ipc: C12Q 1/68 (2006.01) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |